Table 1.
A. Association between NSCLC patients' characteristics and response to gefitinib therapy (N = 50)
VariablesTotal n = 50PR + SD [disease-controlled cases; n = 20 (8 PR + 12 SD)]PD Progressive disease case n = 30P value
Gender
    Male361224NS
    Female1486
Age, y
    Median60.562.0
    Range47-7630-80
Histologic type
    ADC401525NS *
    SCC743
    ASC312
Disease stage
    IIIB936NS **
    IV28919
    Recurrence after surgery1385
Bone metastasis
    Yes1899NS
    No321121
Brain metastasis
    Yes17611NS
    No331419
ECOG PS
    014770.037 ***,
    1261214
    21019
No. prior chemotherapy regimens
    1291316NS ***
    21028
    >21156
Prior cisplatin or carboplatin
    Yes341321NS
    No1679
Smoking history
    Never181170.035 *****
    Former15411
    Current17512
Serum amphiregulin
    Positive142120.026
    Negative361818
Serum TGF-α
    Positive152130.014
    Negative351817
Serum amphiregulin or TGF-α
    Positive223190.001
    Negative281711
B. Cox's proportional hazards model analysis of prognostic factors in patients with advanced NSCLCs who were treated with gefitinib
VariablesHazard ratio (95% CI)P value
Unvariate analysis
    AREG (+/−)2.235 (1.050-4.761)0.037
    TGFA (+/−)3.315 (1.557-7.059)0.002
    AREG or TGFA (+/−)2.510 (1.197-5262)0.018
    Age (65≥/<65)1.044 (0.487-2.237)0.912
    Gender (male/female)1.555 (0.885-3.532)0.291
    Histological type (others/ADC )1.613 (0.848-4.013)0.309
    Disease Stage (IIIB/others)1.088 (0.445-2.706)0.8390
    Perpormance status (2/0-1)6.707 (2.544-17.682)0.001 *
    Smoking history (smoker/never smoker)1.596 (0.736-3.462)0.237
Unvariate analysis
    AREG (+/−)1.042 (0.384-2.825)0.835
    TGFA (+/−)2.457 (1.072-5.625)0.034
    Perpormance status (2/0-1)4.792 (1.420-18.171)0.012
  • Abbreviations: ADC, adenocarcinoma; SCC, squamous cell carcinoma; ASC, adenosquamous cell carcinoma; NS, not significant.

  • * Adenocarcinoma versus other histology (squamous cell carcinoma and adenosquamous cell carcinoma).

  • ** IIIB versus others.

  • *** PS 0-1 versus PS 2.

  • **** Previous chemotherapy 0-1 versus others.

  • ***** Never versus others.

  • P < 0.05 (Fisher's exact test).

  • NS: no significance